Articles Tagged 'Healthcare'

FierceBiotech: Better Therapeutics adds digital treatment into Glooko’s diabetes management platform

BioWorld Insider Podcast: Better Times Ahead for the Biopharma Sector? Could be, the New Numbers Say

FierceBiotech: A new day for pediatric cancer patients: Day One's share price doubles on initial data for brain tumor drug

SF Business Times: Global vision for women's health lands Antiva $31M

Bloomberg: Hg’s Intelerad to buy Ambra Health for $250M+ in radiology software deal

Fierce Biotech: Tyra Biosciences named to 2021 Fierce 15 List

Fierce Biotech: Tyra Biosciences banks $173M to bring cancer resistance programs into clinic

The Long Run Podcast: Julie Grant and Sam Blackman on cancer drugs for kids

Endpoints News: Pfizer bets $1B cash on the original protein degraders as technology nears prime time

Fierce Biotech: Biotech Pfizer funnels $1B into protein degrader Arvinas, with more in biobucks on the table

Silicon Valley Business Journal: Investors pile on Stanford spinout promising new ways to attack cancer, autoimmune diseases

In Vivo: The talent crisis – How to improve recruitment and retain biopharma employees

In Vivo: Biotech’s double-edged sword – Extraordinary funding run contributes to talent crisis

Endpoints News: It’s a new $DAWN for Day One as startup pivots to an IPO for more funding to back its work in pediatric cancer

Fierce Biotech: Qlaris, armed with $25M round, pushes new glaucoma drug into clinic

Forbes: Nearly 50% of venture-backed healthcare companies have no women on the board, new report shows

Endpoints News: Why do some targeted cancer therapies stop working? For Tyra, that's the $106M question

FierceBiotech: Tyra Biosciences banks $106M, adds to C-suite as it aims for the clinic in 2022

FierceBiotech: Glooko raises $30M to expand digital diabetes efforts

Vaccinating with speed and equity: A conversation with Dr. Rebecca Weintraub

Fierce Biotech: Childhood cancer-focused Day One banks $130M for pan-RAF inhibitor

SF Business Times: Targeting more childhood cancers, Day One raises $130M

Endpoints News: With 'rapid' progress of pediatric brain cancer treatment, Day One sees broad excitement in new crossover round

Timmerman Report: No longer an afterthought -- Day One raises $130M for childhood cancer therapies

Fierce Biotech: Rallybio hires Tuch from BMO to lead corporate development

Fierce Biotech: Ideaya, Spelman College team up to provide young African American women a stepping stone to biotech careers

Nina Kjellson: More than words. Extreme(ly) satisfying steps together towards greater health equity

Endpoints News: Vivace Therapeutics scores $30M Series C to take oncology candidate for 'Hippo' pathway to human trial next year

Fierce Biotech: Vivace snares $30M to push Hippo-targeting drugs into the clinic

FierceBiotech: Arvinas eyes a busy 2021 as protein degraders gather steam in breast, prostate cancers

MedCity News: Consumer awareness, needs generating shifts in precision medicine landscape

C&EN: The year in pharma - IPO window remained wide open

Endpoints News: Canaan raises another $800M as it launches its next fund with an emphasis on biotech

BioCentury: Gilead BD head Bender takes top job at pediatric cancer start-up Day One

Fierce Biotech: Childhood cancer-focused Day One snags Gilead alum Bender for CEO

Fierce Biotech: Synthekine debuts with $82M, Stanford tech to create a new generation of cytokine therapies

Endpoints News: A longtime CytomX exec re-emerges at Synthekine, an $82M Stanford spinout

Fierce Biotech: Nocion grabs new CMO as it kicks off COVID-19 cough study

Business Insider: Meet the 21 biotech startups that top VCs say are poised to take off in the next 12 months

Endpoints News: Gilead lines up a $1.55B biotech buyout deal as CEO Dan O’Day invests in his latest cancer blockbuster dream

MedCityNews: Julie Grant on how the pandemic has changed investing

BioCentury: With equity-and-option deal for Tizona, Gilead places latest bet on cancer immunosuppression

FierceBiotech: Partnered and backed by AbbVie, but cancer I-O biotech Tizona targeted by Gilead

FierceBiotech: COVID-19 close-up: Nocion CEO Batycky on controlling cough to control spread

Endpoints News: Billions on the table, GSK’s Hal Barron antes $120M cash to partner with Ideaya

Fierce Biotech: GlaxoSmithKline pens $120M upfront synthetic lethality cancer pact with Fierce 15 winner Ideaya

BioCentury: With Ideaya deal, GSK bulks up synthetic lethality side of oncology business

Nina Kjellson: Biotechnology in the time of COVID-19

Timmerman Report: Finding a path in biotech VC - Nina Kjellson on The Long Run Podcast

Business Insider: Meet the 26 healthcare startups that top VCs say are poised to take off amid the coronavirus pandemic

WSJ Pro VC: Cancer drugmaker Day One Biopharmaceuticals launches with $60 million

STAT News: Startup Spotlight - Aiming to speed precision cancer therapies to children

Julie Grant: Cancer drug development comes of age - The inspiration behind Day One Biopharmaceuticals

FierceBiotech: Day One debuts with $60M to change cancer care—starting with children

FierceBiotech: Arvinas unveils first-in-human data for novel protein degrader in prostate cancer

Bio-IT World: Lessons from personalized medicine can supercharge coronavirus testing

Endpoints News: Roche makes a platform play, betting $190M in cash on Arrakis’ long-haul plans to drug RNA

STAT News: Roche partners with Arrakis Therapeutics to develop drugs that target RNA

FierceBiotech: Biotech Arrakis, Roche team up on RNA-targeting drugs in $190M deal

MedCity News: How are healthcare VCs in every sector handling Covid-19?

Timmerman Report: Do's and don'ts of staying connected in a time of social distancing

BioCentury: We’ve moved on from nude women parties. That’s only a small part of the progress.

CNBC: ‘Ditch the Disk’ group of tech execs is spurring the medical industry to move on from CD-ROMs

San Francisco Business Times: "Say it" - Nina Kjellson, Amy DuRoss and Gail Maderis on the barriers to funding women's health issues

Timmerman Report: First buy, then invest - Novartis, Gilead join $35M bet on Vineti's software

BioCentury: Beyond PROTACs and the proteasome - broadening the TAC toolbox

CNBC: These start-ups are racing to help doctors detect cancer early with a simple blood test

WoVen Podcast: The woman who gets inside the heads of execs at Facebook, Google and more - A conversation with Glo Harris

Endpoints News: RA Capital, Canaan help infuse $50M into Alta-incubated biotech battling acquired resistance to TKIs

BioCentury: Pact’s $75M series C gives Vida’s Kite alumni long-sought stab at personalized cell therapy

Announcing three team promotions

FierceBiotech: Tyra Biosciences takes aim at treatment-resistant tumors with $50M raise

STAT News: Amy DuRoss - To make advanced therapies, we need to industrialize personalization

Endpoints News: Canaan backs Pathios' search for small molecule drugs that hit 'orphan' GCPR

WoVen Podcast: Democratizing healthcare with activist roots - A conversation with Amy DuRoss

FierceBiotech: Canaan Partners promotes Julie Grant to general partner

FierceBiotech: Hyalex snags medtech vet Mark Roby as R&D Chief

Xconomy: With $9.5M, Intrepida Bio launches to target pancreatic cancer & more

EY Pulse on the Industry Report: Wende Hutton offers a perspective on the today's medtech investment climate

FierceBiotech: Nocion Therapeutics named to Fierce 15

WoVen Podcast: Working with grit (and a patient's perspective) in women’s health - A conversation with Gail Maderis

FierceBiotech: A personalized CAR-T to attack every solid tumor? PACT Pharma has a plan

WoVen Podcast: Blazing a trail (and building a family) as a pioneering VC - A conversation with Ginger More

MedCityNews: Pact Pharma enrolls first patients in Phase Ia/Ib solid tumor cell therapy study

Wired: These protein picker-uppers keep your cells clean and healthy

WoVen Podcast: Crafting success (and balance) in venture - A conversation with Wende Hutton

Endpoints News: Bayer enlists Arvinas on two-pronged protein degradation effort, foraying into agtech

Welcome Nils Lonberg

WoVen Podcast: Breaking ground (and battling bias) in brain surgery - A conversation with Dr. Odette Harris

Nina Kjellson: Introducing the WoVen Podcast, a series that celebrates remarkable women in healthcare, tech & business

Tim Shannon in BioCentury: Making orphan drug prices work for society

Endpoints News: Four biotechs, including NextCure, haul in $303M+ from a fresh burst of IPOs

Business Insider: Scientists are working on cancer treatments that attack the disease's 'Holy Grail"

BioCentury: Vineti is keeping cell therapies on track

STAT News: Nils Lonberg, the entrepreneur behind the cancer immunotherapy revolution

STAT News: Arrakis' lofty goal: Kill cancer with pills that target RNA instead of proteins

FierceBiotech: Nocion launches with $27M and 'charged drugs' to selectively target pain

Business Insider: Nocion raises $27M to make a new kind of painkiller as the race to replace opioids heats up

STAT News: How one company, Nocion, thinks unraveling cough can provide a new way to treat pain

Julie Grant: Announcing Nocion Therapeutics, a novel approach to neurogenic inflammation

Nature: Protein-slaying drugs could be the next blockbuster therapies

Nature Reviews: First targeted protein degrader, developed by Arvinas, hits the clinic

FierceBiotech: Glooko makes its management app free to any person with diabetes

BioCentury: Wende Hutton on mapping microbiome manufacturing

Endpoints News: Canaan leaps into UK biotech, co-leading $14M Series A for upstart Grey Wolf

Business Insider: Wende Hutton and top VCs give their best 2019 predictions for healthcare

Fierce Biotech: Brent Aherns & 2019’s medtech industry to weigh hype and realism in equal parts

SF Business Times: Antiva CEO draws on personal experience to fuel drug development

Nasdaq: Cancer biotech Arvinas prices upsized IPO at $16

Business Insider: Julie Grant named 40-and-under Silicon Valley biotech investing star

BioCentury: Sweet switch - Glooko & Novo Nordisk A/S partner on diabetes monitoring app

STAT News: Antiva tried to drum up interest for a much-needed drug. Many men didn’t get it

Nina Kjellson: "Jumping together" to move the field of personalized cancer therapy

BioCentury: Why GV and Canaan backed PACT Pharma's hyperpersonalized cancer approach

Endpoints News: Brent Aherns weights in on FDA's new reimbursement idea for antibiotics

Tim Shannon: More hope for cystic fibrosis treatment, and still more to do

Endpoints: Virtual biotech Antiva sets out on a big R&D quest, armed with a $22 million round for an HPV therapy

Scientific American: New thalidomide-like therapy hijacks cells’ trash-disposal system

Fierce Biotech: Mackay’s Rallybio rare disease startup raises $37M in first funding round

Endpoints Under 40 Feature: Julie Grant’s views on the future of biopharma

Nina Kjellson: Practical tips from two male biotech CEOs who are leaning in

Spotlight on Wende Hutton’s 25 years in venture capital

Anil Singhal: My four takeaways from the AACR annual meeting

Nina Kjellson: A critical marriage for science and health tech

IDEAYA & the Next Frontier in Synthetic Lethality

Business Insider: Wende Hutton shares her best career advice

Cheddar TV: Ambra CEO Morris Panner

Cigna collaborates with Annum Health to introduce a digital health solution to help people reduce alcohol consumption